These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 16389652)

  • 1. Exploring challenges to TTO utilities: valuing states worse than dead.
    Robinson A; Spencer A
    Health Econ; 2006 Apr; 15(4):393-402. PubMed ID: 16389652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A uniform time trade off method for states better and worse than dead: feasibility study of the 'lead time' approach.
    Devlin NJ; Tsuchiya A; Buckingham K; Tilling C
    Health Econ; 2011 Mar; 20(3):348-61. PubMed ID: 21308856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How dead is dead? Qualitative findings from participants of combined traditional and lead-time time trade-off valuations.
    Al Sayah F; Mladenovic A; Gaebel K; Xie F; Johnson JA
    Qual Life Res; 2016 Jan; 25(1):35-43. PubMed ID: 26216584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The gap effect: discontinuities of preferences around dead.
    Stalmeier PF; Busschbach JJ; Lamers LM; Krabbe PF
    Health Econ; 2005 Jul; 14(7):679-85. PubMed ID: 15744750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valuing health status using VAS and TTO: what lies behind the numbers?
    Robinson A; Dolan P; Williams A
    Soc Sci Med; 1997 Oct; 45(8):1289-97. PubMed ID: 9381241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lead time TTO: leading to better health state valuations?
    Attema AE; Versteegh MM; Oppe M; Brouwer WB; Stolk EA
    Health Econ; 2013 Apr; 22(4):376-92. PubMed ID: 22396243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using the Analytic Hierarchy Process to Derive Health State Utilities from Ordinal Preference Data.
    Reddy BP; Adams R; Walsh C; Barry M; Kind P
    Value Health; 2015 Sep; 18(6):841-5. PubMed ID: 26409612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The lead time tradeoff: the case of health states better than dead.
    Pinto-Prades JL; Rodríguez-Míguez E
    Med Decis Making; 2015 Apr; 35(3):305-15. PubMed ID: 25009190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On the assessment of preferences for health and duration: maximal endurable time and better than dead preferences.
    Stalmeier PF; Lamers LM; Busschbach JJ; Krabbe PF
    Med Care; 2007 Sep; 45(9):835-41. PubMed ID: 17712253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The validity of time trade-off values in calculating QALYs: constant proportional time trade-off versus the proportional heuristic.
    Dolan P; Stalmeier P
    J Health Econ; 2003 May; 22(3):445-58. PubMed ID: 12683961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Valuation of pemphigus vulgaris and pemphigus foliaceus health states: a convenience sample experiment.
    Rencz F; Brodszky V; Stalmeier PF; Tamási B; Kárpáti S; Péntek M; Baji P; Mitev AZ; Gulácsi L
    Br J Dermatol; 2016 Sep; 175(3):593-9. PubMed ID: 27062497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protocols for time tradeoff valuations of health states worse than dead: a literature review.
    Tilling C; Devlin N; Tsuchiya A; Buckingham K
    Med Decis Making; 2010; 30(5):610-9. PubMed ID: 20068144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Impact of Different DCE-Based Approaches When Anchoring Utility Scores.
    Norman R; Mulhern B; Viney R
    Pharmacoeconomics; 2016 Aug; 34(8):805-14. PubMed ID: 27034244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The utility assessment method order influences measurement of parents' risk attitude.
    Finnell SM; Carroll AE; Downs SM
    Value Health; 2012; 15(6):926-32. PubMed ID: 22999143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deriving time discounting correction factors for TTO tariffs.
    Attema AE; Brouwer WB
    Health Econ; 2014 Apr; 23(4):410-25. PubMed ID: 23564665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Learning effects in time trade-off based valuation of EQ-5D health states.
    Augestad LA; Rand-Hendriksen K; Kristiansen IS; Stavem K
    Value Health; 2012; 15(2):340-5. PubMed ID: 22433766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are people consistent when trading time for health?
    Oliver A; Wolff J
    Econ Hum Biol; 2014 Dec; 15():41-6. PubMed ID: 24953641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges to time trade-off utility assessment methods: when should you consider alternative approaches?
    Boye KS; Matza LS; Feeny DH; Johnston JA; Bowman L; Jordan JB
    Expert Rev Pharmacoecon Outcomes Res; 2014 Jun; 14(3):437-50. PubMed ID: 24832003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of alternative variants of the lead and lag time TTO.
    Devlin N; Buckingham K; Shah K; Tsuchiya A; Tilling C; Wilkinson G; van Hout B
    Health Econ; 2013 May; 22(5):517-32. PubMed ID: 22715069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using a discrete choice experiment to estimate health state utility values.
    Bansback N; Brazier J; Tsuchiya A; Anis A
    J Health Econ; 2012 Jan; 31(1):306-18. PubMed ID: 22197308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.